Oral high dose ascorbic acid treatment for one year in young CMT1A patients: A randomised, double-blind, placebo-controlled phase II trial

BMC Medicine

Volumn 7, Issue , 2009, Pages

  Verhamme, Camiel ^a   de Haan, Rob J ^a   Vermeulen, Marinus ^a   Baas, Frank ^a   de Visser, Marianne ^a   van Schaik, Ivo N ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; PLACEBO; VITAMIN;

ABDOMINAL CRAMP; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; KIDNEY COLIC; KIDNEY DISEASE; LATENT PERIOD; MALE; MEDIAN NERVE; MOTOR NERVE CONDUCTION; MUSCLE ACTION POTENTIAL; MUSCLE STRENGTH; NAUSEA; NEPHROLITHIASIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; SENSORIMOTOR FUNCTION; TOOTH DISEASE; TREATMENT DURATION; DRUG EFFECT; HOSPITALIZATION; NERVE CONDUCTION; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; SENSATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ASCORBIC ACID; CHARCOT-MARIE-TOOTH DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEDIAN NERVE; MUSCLE STRENGTH; NEURAL CONDUCTION; PLACEBOS; SENSATION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAMINS; YOUNG ADULT;

EID: 71049172916     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-7-70     Document Type: Article

References (29)

1. Nelis E, Van Broeckhoven C, De Jonghe P, Lofgren A, Vandenberghe A, Latour P, Le Guern E, Brice A, Mostacciuolo ML, Schiavon F, Palau F, Bort S, Upadhyaya M, Rocchi M, Archidiacono N, Mandich P, Bellone E, Silander K, Savontaus ML, Navon R, Goldberg-Stern H, Estivill X, Volpini V, Friedl W, Gal A. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet 1996, 4:25-33.
2. Gabreëls-Festen AA, Joosten EM, Gabreëls FJ, Jennekens FG, Janssen-van Kempen TW. Early morphological features in dominantly inherited demyelinating motor and sensory neuropathy (HMSN type I). J Neurol Sci 1992, 107:145-154. 10.1016/0022-510X(92)90282-P, 1564512.
3. Robaglia-Schlupp A, Pizant J, Norreel JC, Passage E, Saberan-Djoneidi D, Ansaldi JL, Vinay L, Figarella-Branger D, Levy N, Clarac F, Cau P, Pellissier JF, Fontés M. PMP22 overexpression causes dysmyelination in mice. Brain 2002, 125:2213-2221. 10.1093/brain/awf230, 12244079.
4. Garcia A, Combarros O, Calleja J, Berciano J. Charcot-Marie-Tooth disease type 1A with 17p duplication in infancy and early childhood: a longitudinal clinical and electrophysiologic study. Neurology 1998, 50:1061-1067.
5. Killian JM, Tiwari PS, Jacobson S, Jackson RD, Lupski JR. Longitudinal studies of the duplication form of Charcot-Marie-Tooth polyneuropathy. Muscle Nerve 1996, 19:74-78. 10.1002/(SICI)1097-4598(199601)19:1<74::AID-MUS10>3.0.CO;2-3, 8538673.
6. Shy ME, Chen L, Swan ER, Taube R, Krajewski KM, Herrmann D, Lewis RA, McDermott MP. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008, 70:378-383. 10.1212/01.wnl.0000297553.36441.ce, 18227419.
7. Verhamme C, van Schaik IN, Koelman JH, De Haan RJ, de Visser M. The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain 2009,
8. Berciano J, Garcia A, Calleja J, Combarros O. Clinico-electrophysiological correlation of extensor digitorum brevis muscle atrophy in children with Charcot-Marie-Tooth disease 1A duplication. Neuromuscul Disord 2000, 10:419-424. 10.1016/S0960-8966(99)00114-5, 10899448.
9. Verhamme C, van Schaik IN, Koelman JH, De Haan RJ, Vermeulen M, De Visser M. Clinical disease severity and axonal dysfunction in hereditary motor and sensory neuropathy Ia. J Neurol 2004, 251:1491-1497. 10.1007/s00415-004-0578-x, 15645349.
10. Kaya F, Belin S, Bourgeois P, Micaleff J, Blin O, Fontes M. Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul Disord 2007, 17:248-253. 10.1016/j.nmd.2006.12.008, 17303424.
11. Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontes M. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004, 10:396-401. 10.1038/nm1023, 15034573.
12. Food and Nutrition Board Institute of Medicine National Academy of Sciences Dietary reference intakes for vitamin C, Vitamin E, Selenium, and Carotenoids. 2000, Washington DC: National Academy Press., http://www.nap.edu/catalog.php?record_id=9810
13. van Dijk JG, Kamp WIM, van Hilten BJ, van Someren P. Influence of recording site on CMAP amplitude on its variation over a length of nerve. Muscle Nerve 1994, 17:1286-1292. 10.1002/mus.880171107, 7935551.
14. Tjon-A-Tsien AM, Lemkes HH, Kamp-Huyts AJ, van Dijk JG. Large electrodes improve nerve conduction repeatability in controls as well as in patients with diabetic neuropathy. Muscle Nerve 1996, 19:689-695. 10.1002/(SICI)1097-4598(199606)19:6<689::AID-MUS1>3.0.CO;2-6, 8609917.
15. Ploeg RJ, Fidler V, Oosterhuis HJ. Hand-held myometry: reference values. J Neurol Neurosurg Psychiatry 1991, 54:244-247. 1014394, 2030353, 10.1136/jnnp.54.3.244.
16. Solari A, Laura M, Salsano E, Radice D, Pareyson D. Reliability of clinical outcome measures in Charcot-Marie-Tooth disease. Neuromuscul Disord 2008, 18:19-26. 10.1016/j.nmd.2007.09.006, 17964785.
17. Merkies IS, Schmitz PI, Meché FG, van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 2000, 54:943-949.
18. Shy ME, Blake J, Krajewski K, Fuerst DR, Laura M, Hahn AF, Li J, Lewis RA, Reilly M. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005, 64:1209-1214.
19. Weisscher N, Post B, De Haan RJ, Glas CAW, Speelman JD, Vermeulen M. The AMC Linear Disability Score in patients with newly diagnosed Parkinson disease. Neurology 2007, 69:2155-2161. 10.1212/01.wnl.0000295666.30948.9d, 18056579.
20. Merkies IS, Schmitz PI, Meche FG, Samijn JP, van Doorn PA. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002, 72:596-601. 1737884, 11971045, 10.1136/jnnp.72.5.596.
21. Mathiowetz V, Weber K, Kashman N, Volland G. Adult norms for the nine hole peg test of finger dexterity. Occupational Therapy J Research 1985, 5:24-38., http://psycnet.apa.org/?fa=main.doiLanding&uid=1986-05316-001
22. van Dijk JP, Blok JH, Lapatki BG, van Schaik IN, Zwarts MJ, Stegeman DF. Motor unit number estimation using high-density surface electromyography. Clinical Neurophysiology 2008, 119:33-42. 10.1016/j.clinph.2007.09.133, 18037342.
23. Vickers AJ, Altman DG. Statistics Notes: Analysing controlled trials with baseline and follow up measurements. BMJ 2001, 323:1123-1124. 1121605, 11701584, 10.1136/bmj.323.7321.1123.
24. Metz J, Hundertmark U, Pevny I. Vitamin C allergy of the delayed type. Contact Dermatitis 1980, 6:172-174. 10.1111/j.1600-0536.1980.tb05592.x, 7389324.
25. Burns J, Ouvrier RA, Yiu EM, Joseph PD, Kornberg AJ, Fahey MC, Ryan MM. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 2009, 8:537-544. 10.1016/S1474-4422(09)70108-5, 19427269.
26. Toth C. Poor tolerability of high dose ascorbic acid in a population of genetically confirmed adult Charcot-Marie-Tooth 1A patients. Acta Neurol Scand 2009, 120:134-8. 10.1111/j.1600-0404.2008.01134.x, 19154534.
27. Huxley C, Passage E, Robertson AM, Youl B, Huston S, Manson A, Sabéran-Djoniedi D, Figarella-Branger D, Pellissier JF, Thomas PK, Fontés M. Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum Mol Genet 1998, 7:449-458. 10.1093/hmg/7.3.449, 9467003.
28. Ginter E. Endogenous ascorbic acid synthesis and recommended dietary allowances for vitamin C. Am J Clin Nutr 1981, 34:1448-1451.
29. Reilly MM, de JP, Pareyson D. 136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A) 8-10 April 2005, Naarden, The Netherlands. Neuromuscul Disord 2006, 16:396-402. 10.1016/j.nmd.2006.03.008, 16684603.